This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F06%3A00004385%21RIV07-MSM-11150___/
n4http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F06%3A00004385%21RIV07-MSM-11150___
rdf:type
skos:Concept n12:Vysledek
dcterms:description
Mortalita u schizofrenie je dvojnásobná oproti běžné populaci. Polovina těchto úmrtí je připisována kardiovaskulárním příčinám. Hlavním cílem prevence je snížení hladiny LDL cholesterolu. Doporučuje se léčba statiny a změna životního stylu. Do studie vstoupilo 100 pacientů se schizofrenií a těžkou dyslipidemií. Všichni užívali antipsychotika. 52 nemocných užívalo rosuvastatin, ostatním žádný statin nebyl ordinován. Po třech měsících byl hodnocen účinek hypolipidemika na lipidový profil, glukózovou homeostázu a složky metabolického syndromu. Studie začala v roce 2003. Nyní jsou uvedena data, dostupná do prosince 2005. Po tříměsíční léčbě statinem byl pozorován výrazný pokles triglyceridů, celkového cholesterolu, LDL cholesterolu a non-HDL cholesterolu. Rozdíl oproti pacientům bez léčby statinem byl vysoce statisticky významný. Nebyl prokázán účinek statinu na HDL cholesterol, body mass index, obvod pasu nebo glukózovou homeostázu. Statin však ovlivnil sérovou hladinu triglyceridů. Rosuvastatin se ukáza Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein (LDL) cholesterol is recognized as a primary target for the prevention of cardiovascular mortality according to the National Cholesterol Education Program-Adult Treatment Panel III. Use of lipid-lowering drugs such as statins is recommended when lifestyle changes are not sufficient to reach the LDL goal. The efficacy and safety of rosuvastatin treatment were evaluated in schizophrenic patients. 100 schizophrenic patients with severe dyslipidemia were identified. All were treated with antipsychotics. Fifty-two patients were treated with rosuvastatin and compared with 48 who did not receive statin treatment. All patients were screened for cardiovascular risk factors and examined at baseline. The effects of lipid-lowering medication on lipid profile, glucose homeostasis, and components of metabolic syndrome were eval Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein (LDL) cholesterol is recognized as a primary target for the prevention of cardiovascular mortality according to the National Cholesterol Education Program-Adult Treatment Panel III. Use of lipid-lowering drugs such as statins is recommended when lifestyle changes are not sufficient to reach the LDL goal. The efficacy and safety of rosuvastatin treatment were evaluated in schizophrenic patients. 100 schizophrenic patients with severe dyslipidemia were identified. All were treated with antipsychotics. Fifty-two patients were treated with rosuvastatin and compared with 48 who did not receive statin treatment. All patients were screened for cardiovascular risk factors and examined at baseline. The effects of lipid-lowering medication on lipid profile, glucose homeostasis, and components of metabolic syndrome were eval
dcterms:title
Léčba závažné dyslipidemie rosuvastatinem u schizofrenie a schizoafektivní poruchy Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
skos:prefLabel
Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder Léčba závažné dyslipidemie rosuvastatinem u schizofrenie a schizoafektivní poruchy Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
skos:notation
RIV/00216208:11150/06:00004385!RIV07-MSM-11150___
n5:strany
1889;1896
n5:aktivita
n14:Z
n5:aktivity
Z(MSM0021620816)
n5:cisloPeriodika
12
n5:dodaniDat
n7:2007
n5:domaciTvurceVysledku
n10:5697905
n5:druhVysledku
n17:J
n5:duvernostUdaju
n13:S
n5:entitaPredkladatele
n11:predkladatel
n5:idSjednocenehoVysledku
504342
n5:idVysledku
RIV/00216208:11150/06:00004385
n5:jazykVysledku
n18:eng
n5:klicovaSlova
dyslipidemia; rosuvastatin; schizophrenia; schizoaffective disorder
n5:klicoveSlovo
n6:dyslipidemia n6:rosuvastatin n6:schizoaffective%20disorder n6:schizophrenia
n5:kodStatuVydavatele
US - Spojené státy americké
n5:kontrolniKodProRIV
[9BCDD7454F39]
n5:nazevZdroje
Journal of Clinical Psychiatry
n5:obor
n16:FL
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
8
n5:rokUplatneniVysledku
n7:2006
n5:svazekPeriodika
67
n5:tvurceVysledku
Kalnická, Dita
n5:zamer
n15:MSM0021620816
s:issn
0160-6689
s:numberOfPages
8
n4:organizacniJednotka
11150